NCT01682616 - A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 25, 2012

Primary Completion Date

June 23, 2022

Study Completion Date

June 23, 2022

Conditions

Small Lymphocytic LymphomaChronic Lymphocytic Leukemia

Interventions

DRUG

ABT-199

ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.

DRUG

Rituximab

Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.

Trial Locations (6)

Peter MacCallum Cancer Ctr /ID# 70394, Melbourne

The Royal Melbourne Hospital /ID# 70393, Parkville

North Shore University Hospital /ID# 71813, New Hyde Park

Moores Cancer Center at UC San Diego /ID# 70398, La Jolla

Northwestern University Feinberg School of Medicine /ID# 71593, Chicago

Duke Cancer Center /ID# 71393, Durham